FcRH5 (also known as FcRL5, IRTA2, or CD307) has been identified as an attractive B cell lineage-specific surface marker in myeloma (Elkins et al., 2012, Hatzivassiliou et al., 2001, Polson et al., 2006). This evidence concerns the gene FCRL5 and plasma cell myeloma.